Get started
Author

M Asuncion Echeveste

Observed names: M A Echeveste, Maria Asuncion Echeveste, Maria Asunción Echeveste, Maria Asunción Echeveste, Maria-Asuncion Echeveste, María Asunción Echeveste, María-Asunción Echeveste
Observed institutions: Hospital Universitario La Paz, Hospital Clínico San Carlos, Hospital Clínic de Barcelona, Hospital Universitario de La Princesa, Clinica Universidad de Navarra, Donostiako Unibertsitate Ospitalea, Centro de Investigación Biomédica en Red de Cáncer, Centro de Investigación Médica Aplicada, Heinrich Heine University Düsseldorf
OpenAlex ID: A5113778731
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials
2017 · Juan-Jose Lahuerta, Bruno Paiva, et al. · Journal of Clinical Oncology · 317
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma
2011 · Bruno Paiva, Norma C. Gutiérrez, et al. · Blood · 300
PDF
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
2016 · Bruno Paiva, Maria-Teresa Cedena, et al. · Blood · 149
PDF
Differentiation stage of myeloma plasma cells: biological and clinical significance
2016 · B Paiva, N Puig, et al. · Leukemia · 109
PDF
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance
2016 · Bruno Paiva, Luis A. Corchete, et al. · Blood · 106
PDF
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
2017 · Wojciech Jurczak, Ilídia Moreira, et al. · The Lancet Haematology · 83
Prognostic Value of Immune Profiling Multiple Myeloma Patients during Minimal Residual Disease Monitoring in the Pethema/GEM2010MAS65 Study
2015 · Paula Arana, Bruno Paiva, et al. · Blood · 65
Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
2017 · A Chanan-Khan, M Egyed, et al. · Leukemia · 28
PDF
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial
2015 · María-Victoria Mateos, Albert Oriol, et al. · Haematologica · 25
PDF
Multiparameter Flow Cytometry Evaluation of Plasma Cell DNA Content and Proliferation in 595 Transplant-Eligible Patients with Myeloma Included in the Spanish GEM2000 and GEM2005<65y Trials
2012 · Bruno Paiva, María-Belén Vídriales, et al. · American Journal Of Pathology · 25
PDF
Comparison Of Sequential Vs Alternating Administration Of Bortezomib, Melphalan and Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) In Elderly Patients With Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial
2013 · Maria-Victoria Mateos, Joaquín Martínez-López, et al. · Blood · 16
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing
2018 · Yanira Ruiz-Heredia, Beatriz Sánchez-Vega, et al. · Haematologica · 15
PDF
Comparison of Sequential Vs Alternating Administration of Bortezomib, Melphalan, Prednisone (VMP) and Lenalidomide Plus Dexamethasone (Rd) in Elderly Pts with Newly Diagnosed Multiple Myeloma (MM) Patients: GEM2010MAS65 Trial
2014 · Maria-Victoria Mateos, Joaquin Martinez-Lopez, et al. · Blood · 8
Clinical Significance of Sensitive Flow-MRD Monitoring in Elderly Multiple Myeloma Patients on the Pethema/GEM2010MAS65 Trial
2014 · Bruno Paiva, Maria Angeles Montalbán, et al. · Blood · 6
Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials
2015 · Bruno Paiva, Noemi Puig, et al. · Blood · 4
The Relevance of Minimal Residual Disease (MRD) Monitoring in Elderly Multiple Myeloma (MM) Patients
2015 · Bruno Paiva, Teresa Cedena, et al. · Blood · 3
Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study
2013 · Francis J Giles, Michele Baccarani, et al. · Blood · 3
Phase 2 Study Of Bendamustine, Bortezomib (Velcade) and Prednisone (BVP) For Newly Diagnosed Multiple Myeloma (MM)
2013 · Maria-Victoria Mateos, Albert Oriol, et al. · Blood · 3
The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients with MDS/AML-Related Somatic Mutations and Inferior Survival
2016 · Bruno Paiva, Noemi Puig, et al. · Blood · 1
Defining the Differentiation Stage of Multiple Myeloma Plasma Cells: Biological and Clinical Significance
2014 · Bruno Paiva, Noemi Puig, et al. · Blood · 1
Overall Safety and Treatment Duration in Lenalidomide (LEN)-, Thalidomide (THAL)-, and Bortezomib (BORT)-Treated Patients (Pts) within the European Post-Approval Safety Study (EU PASS) of Relapsed/Refractory Multiple Myeloma (RRMM)
2012 · Barbara Gamberi, Charalampia Kyriakou, et al. · Blood · 1
The Presence of MDS-like Phenotypic Abnormalities (MDS-PA) Identifies Newly Diagnosed Multiple Myeloma (MM) Patients With MDS/AML-Related Somatic Mutations And Inferior Survival
2017 · Bruno Paiva, Noemi Puig, et al. · Clinical Lymphoma Myeloma & Leukemia
Ultra-Deep Targeted Sequencing Does Not Identify MM Patients with Different Prognosis: Results from a Randomized Phase II Clinical Trial
2016 · Yanira Ruiz-Heredia, Joaquín Martínez-López, et al. · Blood
Simplified in-House Deep Sequencing Method of Inmunoglobulin Genes for Minimal Residual Dissease Quantification and Risk Stratification in Multiple Myeloma
2015 · Beatriz Sanchez-Vega, Santiago Barrio, et al. · Blood
Comparison Between First-Generation 4-Color Vs. Second-Generation 8-Color Multiparameter Flow Cytometry (MFC) to Monitor Minimal Residual Disease (MRD) in Multiple Myeloma (MM)
2015 · Paula Arana, Bruno Paiva, et al. · Blood
Works count: 30
Citation count: 1,268
H-index: 12
I10-index: 12
Year
Topic
Type